Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

At Four Years, Treatment Effect Maintained in More Than Two-Thirds of Patients Who Received Genzyme’s Lemtrada in Pivotal Studies
A Randomized Controlled Trial of Cognitive Behavioral Therapy (CBT) for Adjusting to Multiple Sclerosis (the saMS Trial): Does CBT Work and for Whom Does It Work?
Magnetic Resonance Imaging of Optic Neuritis in Patients With Neuromyelitis Optica Versus Multiple Sclerosis.
Acorda Announces Initiation of Phase 3 Clinical Trial for Dalfampridine in Post-Stroke Walking Deficits
Outcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis.
Santhera Receives European Marketing Authorization for Raxone® in Leber's Hereditary Optic Neuropathy (LHON)
Axoskeletal proteins prevent oligodendrocyte from toxic injury by upregulating survival, proliferation, and differentiation in vitro.
Dalfampridine Improves Sensorimotor Function in Rats With Chronic Deficits After Middle Cerebral Artery Occlusion.
Multiple sclerosis and bipolar disorders: The burden of comorbidity and its consequences on quality of life.
Innovation at RUSH
Exploring the human tear fluid: discovery of new biomarkers in multiple sclerosis.
Causes of Death among Commercially Insured Multiple Sclerosis Patients in the United States.
Neurorestorative effect of FTY720 in a rat model of Alzheimer's disease: Comparison with Memantine.
MR imaging findings of the corpus callosum region in the differentiation between multiple sclerosis and neuromyelitis optica.
Time to see the light.
Quantitative proton density mapping: correcting the receiver sensitivity bias via pseudo proton densities.
Transverse myelitis associated with heroin and cannabis abuse: a new issue from the past.
Cbl-b-deficient mice express alterations in trafficking-related molecules but retain sensitivity to the multiple sclerosis therapeutic agent, FTY720.
Polyunsaturated fatty acids in multiple sclerosis therapy.
FTY720 (Fingolimod) Attenuates Beta-amyloid Peptide (Aβ(42))-Induced Impairment of Spatial Learning and Memory in Rats.
Association between multiple sclerosis and chronic periodontitis: a population-based pilot study.
Novartis acquires all remaining rights to GSK's Ofatumumab to develop treatments for MS and other autoimmune indications
Posterior brain damage and cognitive impairment in pediatric multiple sclerosis.
Cryptococcal meningitis in a multiple sclerosis patient taking natalizumab.
Finax: Cheap Buy Cod

Pages